Literature DB >> 18724573

Privatization in a publicly funded health care system: the U.S. experience.

David U Himmelstein1, Steffie Woolhandler.   

Abstract

The United States has four decades of experience with the combination of public funding and private health care management and delivery, closely analogous to reforms recently enacted or proposed in many other nations. Extensive research, herein reviewed, shows that for-profit health institutions provide inferior care at inflated prices. The U.S. experience also demonstrates that market mechanisms nurture unscrupulous medical businesses and undermine medical institutions unable or unwilling to tailor care to profitability. The commercialization of care in the United States has driven up costs by diverting money to profits and by fueling a vast increase in management and financial bureaucracy, which now consumes 31 percent of total health spending. The Veterans Health Administration system--a network of government hospitals and clinics--has emerged as the leader in quality improvement and information technology, indicating the potential for public sector excellence and innovation. The poor performance of U.S. health care is directly attributable to reliance on market mechanisms and for-profit firms, and should warn other nations from this path.

Mesh:

Year:  2008        PMID: 18724573     DOI: 10.2190/HS.38.3.a

Source DB:  PubMed          Journal:  Int J Health Serv        ISSN: 0020-7314            Impact factor:   1.663


  2 in total

1.  Ethical issues raised by private practice physiotherapy are more diverse than first meets the eye: recommendations from a literature review.

Authors:  Anne Hudon; Marie-Josée Drolet; Bryn Williams-Jones
Journal:  Physiother Can       Date:  2015       Impact factor: 1.037

Review 2.  ICTs and the challenge of health system transition in low and middle-income countries.

Authors:  Gerald Bloom; Evangelia Berdou; Hilary Standing; Zhilei Guo; Alain Labrique
Journal:  Global Health       Date:  2017-08-07       Impact factor: 4.185

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.